CAMBRIDGE, UK 28 March 2007 - CeNeS Pharmaceuticals plc (AIM: CEN) the Cambridge based biopharmaceutical company, announces the filing of its first Investigational New Drug ("IND") application with the US Food and Drug Administration ("FDA") to commence clinical studies in the US with morphine-6-glucuronide ("M6G"), its novel drug for the treatment of post-operative pain.
